-
Mashup Score: 8
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 8
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
FDA confirms tirzepatide shortage is still over, gives compounders a grace period https://t.co/hK5BeSYUsv
-
-
Mashup Score: 1A Rift in Trump World Over How to Make America Healthier - 4 day(s) ago
Statements by Robert F. Kennedy Jr. and Elon Musk tap into a dispute over whether lifestyle changes or drugs are a better way to treat obesity.
Source: www.nytimes.comCategories: General Medicine News, General HCPsTweet-
A Rift in Trump World Over How to Make America Healthier https://t.co/tgIV2gC1ui
-
-
Mashup Score: 1
RFK Jr. is meeting with nearly two dozen senators this week in a bid to win their support.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
RFK Jr. addressing abortion, vaccines to build support in Senate https://t.co/PSCdvHPNRt
-
-
Mashup Score: 9FDA deputy commissioner Namandjé Bumpus to leave agency - 5 day(s) ago
Bumpus oversaw the FDA’s recent reorganization, including the creation of a more unified human foods center.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
FDA deputy commissioner Namandjé Bumpus to leave agency https://t.co/i0Rh6h3daA
-
-
Mashup Score: 3
At the last minute, Zoë decided to call off her euthanasia. But how do you start over after you’ve said all of your goodbyes?
Source: www.theguardian.comCategories: General Medicine News, General HCPsTweet-
At the last minute, Zoë decided to call off her euthanasia. But how do you start over after you’ve said all of your goodbyes? https://t.co/pA3VpVEOPt
-
-
Mashup Score: 1
Pancreatic surgeon Marty Makary is a long-time critic of the medical establishment who’s now set to regulate food, drugs, and medical devices at the FDA.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
RT @adamfeuerstein: Truth-teller or reflexive contrarian: Which Marty Makary would run the FDA? https://t.co/ER3KqoLOGx via @LizzyLaw_
-
-
Mashup Score: 4
Pfizer expects its 2025 sales and earnings to meet analysts’ forecasts, but there is still room for debate on a company whose stock has struggled.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
Pfizer’s 2025 forecast meets expectations and leaves room for debate https://t.co/z4RSVBouEF via @statnews
-
-
Mashup Score: 6Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance | Pfizer - 5 day(s) ago
Full-Year 2025 Revenue Guidance (1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted (2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted (2) Diluted EPS Operational (3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items (4) Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance (1) and reaffirmed its October 29, 2024 full-year 2024 guidance (1) . The accompanying presentation can be found at www.pfizer.com/investors . Full-Year 2025 Revenue Guidance(1) Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes the
Source: www.pfizer.comCategories: General Medicine News, General HCPsTweet-
$PFE guidance — looks basically in-line. https://t.co/FA61B3k1ic
-
-
Mashup Score: 21
With the drug industry’s waning interest in gene therapy, a family tries a staple of philanthropy: honorary naming.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet-
In her years-long effort to develop a gene therapy for her 7-year-old son Maxwell, Amber Freed is trying something more unorthodox: To name Maxwell’s treatment after the highest-bidding donor. The price, she hopes, is just $1 million. By @jasonmmast https://t.co/5OZws9vaL8
-
FDA confirms tirzepatide shortage is still over, gives compounders a grace period https://t.co/hK5BeSYUsv